Antiemetic — Medication Preventing Nausea and Vomiting

Antiemetics encompass diverse pharmacological classes designed to disrupt signals coordinating the emetic reflex between the brainstem and the gastrointestinal tract. Chemotherapy, radiation, and certain immunotherapies can stimulate enterochromaffin cells in the gut to release serotonin, or act directly on the chemoreceptor trigger zone in the central nervous system, activating neurokinin-1, dopamine, or histamine receptors.

By selectively antagonising these receptors, antiemetic agents block the transmission of nausea signals. Clinical guidelines typically categorise these drugs into serotonin (5-HT3) receptor antagonists, neurokinin-1 (NK1) receptor antagonists, corticosteroids, and dopamine antagonists. They are frequently administered in combination regimens before and after cancer therapy to prevent both acute and delayed emesis.

Uncontrolled nausea and vomiting can lead to severe dehydration, chemical imbalances, malnutrition, and profound physical exhaustion. In severe cases, unmanaged symptoms might force clinicians to delay essential cancer treatments or reduce drug dosages, potentially compromising long-term therapeutic outcomes. Proactive antiemetic management protects your physical strength, improves your quality of life, and helps you complete your planned treatment schedule without unnecessary interruptions.

Antiemetics do not involve direct tumour biomarkers. Instead, doctors assess the emetogenic risk of the specific chemotherapy protocol. Pre-treatment assessments include evaluating patient-specific risk factors, such as age, sex, and history of motion sickness. Baseline and ongoing blood tests monitor renal function, liver enzymes, and serum electrolytes to ensure drugs are metabolised safely.

Antiemetics are relevant across nearly all cancer types where systemic chemotherapy, targeted therapies, or radiation are used. They are particularly vital in regimens for breast cancer, testicular cancer, lung cancer, ovarian cancer, and haematological malignancies such as leukaemia and lymphoma, which frequently employ moderate-to-highly emetogenic cytotoxic agents like cisplatin, cyclophosphamide, or doxorubicin.

Antiemetic prescribing directly correlates with the chosen cancer therapy. Highly emetogenic chemotherapy typically warrants a multi-drug preventative protocol, such as combining an NK1 antagonist, a 5-HT3 antagonist, and dexamethasone. Olanzapine or dopamine antagonists may be added for refractory symptoms. Ensuring symptom control preserves treatment adherence and avoids hospital readmissions.